AVTR Avantor

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries.

Company profile

Michael Stubblefield
Fiscal year end
Former names
Vail Holdco Corp
Applied Silicone Company LLC • Morehouse Cowles LLC • SiTech Nusil, LLC • Therapak, LLC • Avantor Funding, Inc. • Avantor Performance Materials International, LLC • Jencons (Scientific) LLC • Nusil Acquisition Corp. • Nusil Investments LLC • Nusil Technology LLC ...

AVTR stock data



29 Oct 21
4 Dec 21
31 Dec 21
Quarter (USD)
Sep 21 Jun 21 Mar 21 Dec 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Avantor earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Dec 21 Gupta Rajiv Common Stock Sell Dispose S No Yes 39.3 100,000 3.93M 879,347
12 Nov 21 Vanderhaegen Frederic Common Stock Sell Dispose S No No 38.25 80,000 3.06M 154,495
12 Nov 21 Vanderhaegen Frederic Common Stock Option exercise Acquire M No No 23.2 80,000 1.86M 234,495
12 Nov 21 Vanderhaegen Frederic Stock Options Common Stock Option exercise Dispose M No No 23.2 80,000 1.86M 460,830
11 Nov 21 Vanderhaegen Frederic Common Stock Sell Dispose S No No 38.41 60,804 2.34M 154,495
8 Nov 21 Joseph R Massaro Common Stock Grant Acquire A No No 0 745 0 745
1 Nov 21 Gupta Rajiv Common Stock Sell Dispose S No Yes 40.31 100,000 4.03M 979,347

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

95.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 457 428 +6.8%
Opened positions 74 71 +4.2%
Closed positions 45 42 +7.1%
Increased positions 154 172 -10.5%
Reduced positions 175 131 +33.6%
13F shares
Current Prev Q Change
Total value 26.58B 21.84B +21.7%
Total shares 580.57M 553.17M +5.0%
Total puts 1.1M 1.29M -14.5%
Total calls 1.38M 1.35M +2.3%
Total put/call ratio 0.8 1.0 -16.4%
Largest owners
Shares Value Change
TROW T. Rowe Price 72.08M $2.95B +2.6%
Vanguard 48.95M $2B +0.6%
BLK Blackrock 38.22M $1.56B +8.3%
New Mountain Vantage Advisers, L.L.C. 28M $1.15B 0.0%
New Mountain Investments III 28M $788.2M 0.0%
IVZ Invesco 25.62M $1.05B -9.8%
Canada Pension Plan Investment Board 22.7M $928.39M +78.4%
Nuveen Asset Management 20.73M $847.75M +17.4%
Boston Partners 19.58M $800.87M -7.8%
FMR 17.57M $718.49M +20.1%
Largest transactions
Shares Bought/sold Change
Canada Pension Plan Investment Board 22.7M +9.98M +78.4%
Pictet Asset Management 0 -8.72M EXIT
Pictet Asset Management 7.8M +7.8M NEW
Viking Global Investors 7.12M -4.61M -39.3%
Nuveen Asset Management 20.73M +3.08M +17.4%
FMR 17.57M +2.94M +20.1%
BLK Blackrock 38.22M +2.94M +8.3%
IVZ Invesco 25.62M -2.79M -9.8%
Robecosam 2.45M +2.45M NEW
Robeco Institutional Asset Management B.V. 2.54M +2.42M +1967.5%

Financial report summary

  • The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, operating results, cash flows and/or financial condition, the nature and extent of which could be material.
  • Significant interruptions in our operations could harm our business, financial condition and results of operations.
  • We compete in highly competitive markets. Failure to compete successfully could adversely affect our business, financial condition and results of operations.
  • It may be difficult for us to implement our strategies for improving growth.
  • Part of our growth strategy is to pursue strategic acquisitions, which will subject us to a variety of risks that could harm our business.
  • The customers we serve have and will continue to experience significant industry-related changes that could adversely affect our business.
  • Our offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation.
  • The loss of a significant number of customers or a reduction in orders from a significant number of customers could reduce our net sales and harm our operating results.
  • We are subject to risks associated with doing business globally, which may harm our business.
  • Changes in exchange rates can adversely affect our net sales, profits and cash flows.
  • Our business depends on our ability to use and access information systems, and any failure to successfully maintain these systems or implement new systems to handle our changing needs could materially harm our operations.
  • Our inability to protect our intellectual property could adversely affect our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expenses as a result.
  • Our trademarks are valuable assets and if we are unable to protect them from infringement our business prospects may be harmed.
  • We are subject to product liability and other claims in the ordinary course of business.
  • We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive.
  • Our business, financial condition and results of operations depend upon the availability of raw materials.
  • Our business, financial condition and results of operations depend upon maintaining our relationships with suppliers.
  • Our use of chemicals and chemical processes is subject to inherent risk.
  • We are highly dependent on our senior management and key employees.
  • Changes in tax law relating to multinational corporations could adversely affect our tax position.
  • Certain of our businesses rely on relationships with collaborative partners and other third parties for development, supply and marketing of certain products and potential products, and such collaborative partners or other third parties could fail to perform sufficiently.
  • We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies, and our failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition.
  • We are subject to environmental, health and safety laws and regulations, and costs to comply with such laws and regulations, or any liability or obligation imposed under such laws or regulations, could negatively impact our business, financial condition and results of operations.
  • Our indebtedness could adversely affect our financial condition and prevent us from fulfilling our debt or contractual obligations.
  • Despite our current level of indebtedness, we and our subsidiaries may still be able to incur substantially more debt.
  • An increase in interest rates may negatively impact our operating results and financial condition.
  • Our common stock ranks junior to the MCPS with respect to the payment of dividends and amounts payable in the event of our liquidation, dissolution or winding-up of our affairs.
  • Holders of the MCPS have the right to elect two directors in the case of certain dividend arrearages.
  • Because we have no current plans to pay cash dividends on our common stock, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.
  • Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
  • Our amended and restated certificate of incorporation provides, subject to limited exceptions, that state and federal courts (as appropriate) located within the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’
Management Discussion
  • We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted EBITDA by geographic segment based on customer location: Americas, Europe and AMEA. Corporate costs are managed on a standalone basis and not allocated to segments.
  • Third quarter revenue growth reflects strong growth in the biopharma end market, along with modest growth in the healthcare and advanced technologies & applied materials end markets. We continue to generate high single-digit demand in our core business, augmented by our COVID-19 related sales of PPE and solutions to support diagnostic testing and vaccine production. Double-digit growth of our proprietary materials and consumables product group, commercial excellence and productivity contributed to gross margin and Adjusted EBITDA margin expansion.
  • Net sales increased $229.3 million or 14.3%, which included $15.3 million or 0.9% of favorable foreign currency impact and $50.8M or 3.2% of M&A impact. Organic growth in net sales was $163.2 million or 10.2% and was primarily due to strong growth in our core business and a modest contribution from COVID-19 related sales.
Content analysis
8th grade Avg
New words: absence, aerospace, Antylia, bioprocessing, commitment, disruption, found, inflationary, Masterflex, ownership, platform, preliminarily, redemption, Scientific, sequential, structure, unpaid, valuation, widespread
Removed: mid, percentage, timing